Company Stock Price of Becton, Dickinson and Company (BDX) Decreases -0.82%

Becton, Dickinson and Company stock performance trend indicates that the stock price has rallied 10.4% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 2.26% . Looking at the past 52 week period, the stock price is up at 22.33% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Becton, Dickinson and Company has a positive value of 9.94 compared to overall market.Becton, Dickinson and Company is having a Relative Strength Index of 57.31 which indicates the stock is not yet over sold or over bought based on the technical indicators.

Becton, Dickinson and Company (NYSE:BDX) has tumbled 0.82% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 1.6% in the last four weeks. The stocks have underperformed the S&P 500 by 1.06% during the past week but Becton, Dickinson and Company (NYSE:BDX) it has outperformed the index in 4 weeks by 0.44%.

For the current week, the company shares have a recommendation consensus of Buy. Becton, Dickinson and Company (NYSE:BDX) : On Friday heightened volatility was witnessed in Becton, Dickinson and Company (NYSE:BDX) which led to swings in the share price. The stock opened for trading at $181.69 and hit $184.22 on the upside , eventually ending the session at $183.79, with a gain of 1.33% or 2.42 points. The heightened volatility saw the trading volume jump to 1,842,549 shares. The 52-week high of the share price is $186.11 and the company has a market cap of $39,115 million. The 52-week low of the share price is at $146.12 .

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Becton Dickinson and Co was Downgraded by Raymond James to Outperform on Jan 5, 2017. Becton Dickinson and Co was Downgraded by JP Morgan to Neutral on Jan 3, 2017.

Company has reported several Insider transactions to the SEC, on Feb 16, 2017, Jeffrey S Sherman (Sr. VP and General Counsel) sold 31,464 shares at 180.03 per share price.On Feb 15, 2017, Alexandre Conroy (Executive Vice President) sold 8,500 shares at 177.86 per share price.On Dec 16, 2016, John E Gallagher (VP, Corp Finance and Treasurer) sold 1,793 shares at 168.82 per share price.

Becton Dickinson and Co Last issued its quarterly earnings results on Feb 2, 2017. The company reported $2.33 EPS for the quarter, beating the analyst consensus estimate by $ 0.21. Analyst had a consensus of $2.12. The company had revenue of $2922.00 million for the quarter, compared to analysts expectations of $2860.52 million. The companys revenue was down -2.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.96 EPS.

Becton, Dickinson and Co. is engaged principally in the manufacture and sale of a broad line of supplies, devices and systems used by health care professionals, medical research institutions and the general public. BDs operations consist of three worldwide business segments: Medical Systems, Biosciences, and Preanalytical Solutions.


Leave a Reply

Your email address will not be published. Required fields are marked *